Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport.

The yeast Pdr5 multidrug transporter is an important member of the ATP-binding cassette superfamily of proteins. We describe a novel mutation (S558Y) in transmembrane helix 2 of Pdr5 identified in a screen for suppressors that eliminated Pdr5-mediated cycloheximide hyper-resistance. Nucleotides as well as transport substrates bind to the mutant Pdr5 with an affinity comparable with that for wild-type Pdr5. Wild-type and mutant Pdr5s show ATPase activity with comparable K(m)((ATP)) values. Nonetheless, drug sensitivity is equivalent in the mutant pdr5 and the pdr5 deletion. Finally, the transport substrate clotrimazole, which is a noncompetitive inhibitor of Pdr5 ATPase activity, has a minimal effect on ATP hydrolysis by the S558Y mutant. These results suggest that the drug sensitivity of the mutant Pdr5 is attributable to the uncoupling of NTPase activity and transport. We screened for amino acid alterations in the nucleotide-binding domains that would reverse the phenotypic effect of the S558Y mutation. A second-site mutation, N242K, located between the Walker A and signature motifs of the N-terminal nucleotide-binding domain, restores significant function. This region of the nucleotide-binding domain interacts with the transmembrane domains via the intracellular loop-1 (which connects transmembrane helices 2 and 3) in the crystal structure of Sav1866, a bacterial ATP-binding cassette drug transporter. These structural studies are supported by biochemical and genetic evidence presented here that interactions between transmembrane helix 2 and the nucleotide-binding domain, via the intracellular loop-1, may define at least part of the translocation pathway for coupling ATP hydrolysis to drug transport.

The yeast Pdr5p multidrug transporter: how does it recognize so many substrates?

Multidrug transporters are of considerable importance because they present problems in the treatment of infectious disease and cancer. A central issue is the ability of efflux pumps to recognize an astounding array of structurally diverse compounds. The yeast Pdr5p efflux pump, which is a member of the ATP-binding cassette superfamily, has at least 3 substrate-binding sites, each of which appears to use different chemical properties to transport compounds. All Pdr5p substrates, however, have a size requirement that is independent of hydrophobicity.

The role of hydrogen bond acceptor groups in the interaction of substrates with Pdr5p, a major yeast drug transporter.

The yeast ABC (ATP-binding cassette protein) multidrug transporter Pdr5p transports a broad spectrum of xenobiotic compounds, including antifungal and antitumor agents. Previously, we demonstrated that substrate size is an important factor in substrate-transporter interaction and that Pdr5p has at least three substrate-binding sites. In this study, we use a combination of whole cell transport assays and photoaffinity labeling of Pdr5p with [(125)I]iodoarylazidoprazosin in purified plasma membrane vesicles to study the behavior of two series of novel substrates: trityl (triphenylmethyl) and carbazole derivatives. The results indicate that site 2, defined initially by tritylimidazole efflux, requires at least a single hydrogen bond acceptor group (electron pair donor). In contrast, complete inhibition of rhodamine 6G efflux and [(125)I]iodoarylazidoprazosin binding at site 1 requires substrates with three electronegative groups. Carbazole and trityl substrates with two groups show saturating, incomplete inhibition at this site. This type of inhibition is frequently observed in bacterial multidrug-binding proteins that use a pocket with multiple binding sites. The presence of multiple sites with different requirements for substrate-Pdr5p interaction may explain the broad specificity of xenobiotic compounds transported by this protein.

Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.

The yeast (Saccharomyces cerevisiae) multidrug transporter Pdr5p effluxes a broad range of substrates that are variable in structure and mode of action. Previous work suggested that molecular size and ionization could be important parameters. In this study, we compared the relative sensitivity of isogenic PDR5 and pdr5 strains toward putative substrates that are similar in chemical structure. Three series were used: imidazole-containing compounds, trialkyltin chlorides, and tetraalkyltin compounds. We demonstrate that the Pdr5p transporter is capable of mediating transport of substrates that neither ionize nor have electron pair donors and that are much simpler in structure than those transported by the human MDR1-encoded P-glycoprotein. Furthermore, the size of the substrate is critical and independent of any requirement for hydrophobicity. Substrates have surface volumes greater than 90 A(3) with an optimum response at approximately 200-225 A(3) as determined by molecular modeling. Assays measuring the efflux from cells of [(3)H]chloramphenicol and [(3)H]tritylimidazole were used. A concentration-dependent inhibition of chloramphenicol transport was observed with imidazole derivatives but not with either the organotin compounds or the antitumor agent doxorubicin. In contrast, several of the organotin compounds were potent inhibitors of tritylimidazole efflux, but the Pdr5p substrate tetrapropyltin was ineffective in both assays. This argues for the existence of at least three substrate-binding sites on Pdr5p that differ in behavior from those of the mammalian P-glycoprotein. Evidence also indicates that some substrates are capable of interacting at more than one site. The surprising observation that Pdr5p mediates resistance to tetraalkyltins suggests that one of the sites might use only hydrophobic interactions to bind substrates.

Novel Square Arrangements in Tetranuclear and Octanuclear Iron(III) Complexes with Asymmetric Iron Environments Created by the Unsymmetric Bridging Ligand N,N,N'-Tris((N-methyl)-2-benzimidazolylmethyl)-N'-methyl-1,3-diamino-2-propanol.

The synthesis and characterization of novel tetranuclear and octanuclear iron(III) complexes with structures based on a nearly square arrangement of four iron ions are reported. Reaction of ferric nitrate, sodium acetate, and the unsymmetrical binucleating ligand HBMDP, where HBMDP is N,N,N'-tris((N-methyl)-2-benzimidazolylmethyl)-N'-methyl-1,3-diamino-2-propanol, in acetone/water yields the tetranuclear iron complex [Fe(4)(&mgr;-O)(2)(&mgr;-BMDP)(2)(&mgr;-OAc)(2)](4+), which exhibits coordination number asymmetry. The structure of [Fe(4)(&mgr;-O)(2)(&mgr;-BMDP)(2)(&mgr;-OAc)(2)](NO(3))(3)(OH).12H(2)O has been determined by single-crystal X-ray diffraction. Each (&mgr;-BMDP) ligand spans two iron(III) ions and causes these ions to become structurally distinct. Within this binuclear unit one iron atom is five-coordinate with distorted square pyramidal geometry and an N(2)O(3) donor set, while the other iron is six-coordinate with distorted octahedral geometry and an N(3)O(3) donor set. Two of these binuclear units are linked through a pair of oxo and acetato bridges to form the centrosymmetric tetranuclear complex. The coordinatively nonequivalent iron atoms exhibit distinct Mössbauer spectroscopic parameters and produce a pair of doublets at 80 K. The iron(III) centers are coupled antiferromagnetically with a room-temperature moment of 1.9 &mgr;(B) per iron with J = -103.3 cm(-)(1), zJ' = -105.9 cm(-)(1). The properties of the unsymmetric cation [Fe(4)(&mgr;-O)(2)(&mgr;-BMDP)(2)(&mgr;-OAc)(2)](4+) are similar to those observed for binuclear iron proteins with comparable coordinative inequivalence. Efforts to increase the solubility of [Fe(4)(&mgr;-O)(2)(&mgr;-BMDP)(2)(&mgr;-OAc)(2)](4+) by metathesis with sodium tetrafluoroborate resulted in the isolation of crystals of a new octanuclear iron species, [Fe(8)(&mgr;-O)(4)(&mgr;-BMDP)(4)(OH)(4)(&mgr;-OAc)(4)](BF(4))(3)(OH).2CH(3)CN.8H(2)O( )()(2), which has also been characterized by single-crystal X-ray diffraction. The asymmetric unit consists of an Fe(2)(&mgr;-O)(&mgr;-BMDP)(&mgr;-OAc)(OH) group which is externally bridged via the oxo ions to form a molecular square with four of the eight iron ions at the corners. Both iron sites are six-coordinate with distorted octahedral geometry. One has an N(2)O(4) donor set; the other has an N(3)O(3) donor set.